Valuation: 3D Signatures Inc

Market Cap 5.02M 3.6M 3.22M 2.96M 2.69M 342M 5.12M 35.36M 14.19M 180M 13.51M 13.22M 567M P/E 2025
-3.55x
P/E 2026 -1.74x
Enterprise Value 6.13M 4.39M 3.93M 3.62M 3.28M 417M 6.24M 43.14M 17.32M 219M 16.48M 16.13M 692M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
97.02%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 67 31/03/2026
Director of Finance/CFO 56 30/01/2026
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member - 08/09/2016
Director/Board Member - 03/02/2022
Chairman 67 31/03/2026
Change 5-day change 1-year change 3-year change Capi.($)
+32.50%+0.95% - - 3.59M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-3.95%+22.72%+48.57% 45.33B
-0.33%-3.12%+17.62%+117.27% 42.25B
+0.55%+1.93%+229.73%+928.00% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average +3.33%+4.72%+52.88%+164.14% 43.63B
Weighted average by Cap. +0.01%+3.64%+49.57%+162.47%

Financials

2025 2026
Net sales - -
Net income -2.72M -1.95M -1.75M -1.61M -1.45M -185M -2.77M -19.14M -7.68M -97.32M -7.31M -7.16M -307M -2.31M -1.66M -1.48M -1.36M -1.24M -157M -2.35M -16.27M -6.53M -82.72M -6.22M -6.08M -261M
Net Debt -789K -566K -507K -466K -422K -53.71M -804K -5.56M -2.23M -28.25M -2.12M -2.08M -89.1M 1.11M 792K 709K 652K 591K 75.2M 1.13M 7.78M 3.12M 39.56M 2.97M 2.91M 125M
Logo 3D Signatures Inc
Telo Genomics Corp. is a molecular diagnostics company that is engaged in developing the telomere analysis platform Teloview to enable the development of diagnostic and prognostic applications based on the quantification of genomic instability as a disease predictor. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. It quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.
Employees
-